10-Q quarterly report · filed Oct 30, 2026

Gilead Sciences (GILD) Q3 2026 10-Q Quarterly Report

Short answer

Gilead Sciences (GILD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $8.3B (up 6.8% year over year) with net income of $2.4B.

Q3 2026 key financials · XBRL

Revenue
$8.3B
+6.8% YoY · +6.4% QoQ
Net income
$2.4B
−20.4% YoY · +123.2% QoQ
Operating margin
41.7%
EPS (diluted)
$1.95
−19.8% YoY · +123.1% QoQ

Source: XBRL data from the Gilead Sciences (GILD) Q3 2026 10-Q on SEC EDGAR. USD.

Gilead Sciences Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Third-quarter revenue $8.3B, up 7% YoY from $7.769B
  • Product gross margin 81.0% vs 78.6% YoY
  • Best segment HIV: $6.2B, up 18%; worst Veklury: $86M, down 69%
  • Operating cash flow $11.152B versus $6.692B; cash and equivalents $6.4B
  • Near-term headwinds: competitive Cell Therapy demand, lower COVID hospitalizations, $1.75B Trodelvy IPR&D impairment

Risk Factors

  • New pricing risk: Biktarvy selected for Medicare Maximum Fair Price, effective January 2028, with CMS completing price-setting in October 2026
  • Regulatory risk: 100% tariffs on patented pharmaceuticals began taking effect in July 2026, subject to exemptions and potential modifications
  • Clinical-development risk: Phase 3 EVOKE-03 discontinued in June 2026, triggering an impairment charge
  • Operational risk: CAR T-cell manufacturing delays or quality issues could constrain Yescarta and Tecartus supply
  • Financial risk: $32 billion U.S. investment through 2030 could increase capital expenditures, operating expenses and cash-flow variability

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Gilead Sciences quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.